Can Hodgkin lymphoma be cured?

Yes, often. The National Cancer Institute states that "Hodgkin lymphoma can often be cured." Its summary for clinicians is more exact: "up to 90% of all newly diagnosed patients with HL can be cured with combination chemotherapy and/or radiation therapy."

The disease is not common. For 2026 the American Cancer Society projects 8,920 new cases and 1,100 deaths in the United States, and that is the pair of numbers NCI's SEER pages carry. Those two numbers, set side by side, tell you most of what you need to know about the outlook.

What separates it from other lymphomas

Lymphoma is cancer that starts in the lymph system, the network of vessels and nodes that carries immune cells around the body. It splits into two families: Hodgkin lymphoma and non-Hodgkin lymphoma. The dividing line is a cell. NCI describes Reed-Sternberg cells as "large, abnormal lymphocytes (a type of white blood cell) that may contain more than one nucleus." A pathologist who sees them is looking at Hodgkin lymphoma.

There are two main forms, classic and nodular lymphocyte-predominant. The usual first sign is "painless, swollen lymph nodes in the neck, underarm, or groin." Doctors also look for what they call B symptoms: "fever for no known reason, weight loss for no known reason, or drenching night sweats." Drenching means soaking the sheets, not feeling a bit warm. B symptoms affect the stage and the treatment plan, so they are worth reporting precisely.

Stages run from I to IV. Stage I is disease in one place. Stage IV means it has reached organs outside the lymph system, such as the liver or bone marrow. Unlike most cancers, stage IV here is still often curable.

What the treatment is

The long-standing backbone is ABVD, which stands for doxorubicin, bleomycin, vinblastine, and dacarbazine. BEACOPP is a more intensive combination used for higher-risk disease. MOPP is the older regimen these replaced. Two newer drugs have moved into frontline and relapse settings: brentuximab vedotin, an antibody linked to a chemotherapy payload that delivers it to the tumor cell, and nivolumab, an immunotherapy that releases a brake on the immune system. Radiation is added in some plans and left out in others.

The part that reframes the word cured

Cure here is real. It is also the beginning of a long relationship with the medical system, because the treatments that cure Hodgkin lymphoma carry a tail of late effects that can arrive decades later.

The numbers are sobering. NCI's clinician summary puts the cumulative risk of a second solid tumor at roughly 48% by 40 years of follow-up. The risk of cardiac disease may persist for over 30 years after the first treatment. Some chemotherapy drugs, particularly alkylating agents, can cause infertility. Radiation to the neck often leads to hypothyroidism, an underactive thyroid, which is easy to treat once someone thinks to check for it.

Most people with Hodgkin lymphoma are diagnosed young, which is exactly why this matters. A cure at 25 means 50 years of living with the aftermath.

NCI's own conclusion is direct: "regular follow-up by doctors who are experts in finding and treating late effects is important for the long-term health of patients treated for Hodgkin lymphoma."

So two practical things. Before treatment starts, ask about fertility preservation, because the window closes once the first cycle is given. And when treatment ends, ask for a written survivorship plan listing every drug, the total dose of each, the radiation fields used, and the follow-up tests you need and how often. Decades from now, a new doctor will need that document, and you will be the only one who has it.